human fasl recombinant protein  (Adipogen)

Journal: iScience

Article Title: Targeting adrenergic receptors to mitigate invariant natural killer T cells-induced acute liver injury

doi: 10.1016/j.isci.2023.107947

Figure Lengend Snippet:

Article Snippet: Human FasL recombinant protein , Adipogen® , Catalog #: AG-40B-0001-C010.

Techniques: Blocking Assay, Functional Assay, Recombinant, Enzyme-linked Immunosorbent Assay, Staining, Software

Journal: Experimental and Therapeutic Medicine

Article Title: Expression profiling of genes in rheumatoid fibroblast-like synoviocytes regulated by Fas ligand via cDNA microarray analysis

doi: 10.3892/etm.2021.10432

Figure Lengend Snippet: mRNA expression levels of the 3 most upregulated genes by FasL in RA-FLS. RT-qPCR analysis of the relative mRNA expression levels of DUSP6, EREG and IL-11 in RA-FLS after 12 h of incubation with 1,000 ng/ml of FasL or serum-free medium as a control is shown (n =6 for each gene). Control cells were assigned a value of 1. * P<0.05; RT, reverse transcription; RA, rheumatoid arthritis; FLS, fibroblast-like synoviocytes; FasL, Fas ligand; DUSP6, dual specificity phosphatase 6; EREG, epiregulin.

Article Snippet: Four individual cell lines (samples 1-4) of primary cultured RA-FLS (2x10 6 cells/well) were incubated with 1,000 ng/ml of recombinant human FasL protein (R&D Systems) or were left untreated with OPTI-MEM medium (Thermo Fisher Scientific, Inc.) as control for 12 h at 37 ̊C with 5% CO 2 .

Techniques: Expressing, Quantitative RT-PCR, Incubation, Control, Reverse Transcription

Journal: Experimental and Therapeutic Medicine

Article Title: Expression profiling of genes in rheumatoid fibroblast-like synoviocytes regulated by Fas ligand via cDNA microarray analysis

doi: 10.3892/etm.2021.10432

Figure Lengend Snippet: mRNA expression levels of the 3 most downregulated genes by FasL in RA-FLS. RT-qPCR analysis of the relative mRNA expression levels of ANGPTL7, PIAS2 and GDF5 in RA-FLS after 12 h of incubation with 1,000 ng/ml of FasL or serum-free medium as a control is shown (n =6 for each of genes). Control cells were assigned a value of 1. * P<0.05; RT, reverse transcription; RA, rheumatoid arthritis; FLS, fibroblast-like synoviocytes; FasL, Fas ligand; ANGPTL7, angiopoietin-like 7; PIAS2, protein inhibitor of activated STAT 2; GDF5, growth differentiation factor 5.

Article Snippet: Four individual cell lines (samples 1-4) of primary cultured RA-FLS (2x10 6 cells/well) were incubated with 1,000 ng/ml of recombinant human FasL protein (R&D Systems) or were left untreated with OPTI-MEM medium (Thermo Fisher Scientific, Inc.) as control for 12 h at 37 ̊C with 5% CO 2 .

Techniques: Expressing, Quantitative RT-PCR, Incubation, Control, Reverse Transcription

Journal: Stem Cell Reports

Article Title: Immunological Properties of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells

doi: 10.1016/j.stemcr.2018.07.009

Figure Lengend Snippet: The Role of TGF-β, FasL, and PDL1 Signaling in RPE Immunomodulation (A) The percentage of dividing CD3 + T cells was analyzed following staining of PBMCs with CFSE, activation and co-cultured for 4 days with RPE cells in the presence or absence of inhibitors of TGF-β signaling. (B and C) The percentage of apoptotic annexin V + /PI − cells was analyzed after activation and co-cultured for 1 day with RPE cells in the presence or absence of inhibitors of FasL signaling (B) or anti-PDL1 blocking antibody (α-PDL) (C); na, non-activated T cells; act, cells activated with anti-CD3/anti-CD28 antibodies; SB, SB-431542; A83, A-83-01; α-TGF-β, anti-TGF-β antibody; DcR, recombinant human DcR3; α-FasL, anti-FasL antibody. Data are presented as means ± SEM of at least 3 independent experiments. ∗ p ≤ 0.05; ∗∗ p ≤ 0.01, ∗∗∗ p ≤ 0.001.

Article Snippet: The following inhibitors were used: neutralizing anti-PDL1 Ab (2–12 μg/mL, no. AF156), neutralizing anti-FasL Ab (10 ng/mL, no. MAB126), recombinant human DcR3/TNFRSF6B chimeric protein acting as an inhibitor of FasL signaling (0.05–0.2 μg/mL, no. 142-DC-100), neutralizing anti-TGF-β1,2,3 Ab (10 μg/mL, no. MAB1835; all the inhibitors from R&D Systems, Minneapolis, MN), and two small molecules inhibiting TGF-β signaling, A-83-01 (0.1–0.5 μM) and SB-431542 (10 or 20 μM; both from Tocris Bioscience, Bristol, UK).

Techniques: Staining, Activation Assay, Cell Culture, Blocking Assay, Recombinant